Payment overview · 2025
General Payments
$1,240.70
56 reported records · 13 companies
Healthcare provider profile · identity verified
York Sing Chan, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1891010286
Verified facts
What the public records show
CMS Open Payments records show York Sing Chan, D.O. received $1,240.70 in general payments during 2025 across 56 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Nexletol, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexletol by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $376.46 | 30.3% | 16 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $200.17 | 16.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $150.65 | 12.1% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $86.17 | 7.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.63 | 6.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.26 | 6.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.87 | 5.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $49.59 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.24 | 3.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.32 | 3.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.00 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.54 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.80 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,240.70 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $329.21 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $150.65 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $150.65 | 8 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $86.17 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.26 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.72 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| LITFULO Normalized: litfulo |
Drug | PFIZER INC. | $45.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.24 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $40.05 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.45 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| EUCRISA Normalized: eucrisa |
Drug | PFIZER INC. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 107 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 144 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
116 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
144 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
66 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
235 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
108 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Epolamine | Diclofenac Epolamine | 1245 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 1082 | 246 |
| Atorvastatin Calcium | Atorvastatin Calcium | 944 | 215 |
| Vascepa | Icosapent Ethyl | 836 | 169 |
| Diclofenac Sodium | Diclofenac Sodium | 803 | 196 |
| Simvastatin | Simvastatin | 682 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 669 | 156 |
| Losartan Potassium | Losartan Potassium | 664 | 152 |
| Metformin Hcl | Metformin Hcl | 542 | 106 |
| Fluticasone Propionate | Fluticasone Propionate | 520 | 119 |
| Ammonium Lactate | Ammonium Lactate | 472 | 133 |
| Azelastine Hcl | Azelastine Hcl | 435 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 427 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 427 | 99 |
| Montelukast Sodium | Montelukast Sodium | 387 | 130 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 383 | 69 |
| Omeprazole | Omeprazole | 373 | 129 |
| Fluocinonide | Fluocinonide | 367 | 105 |
| Zolpidem Tartrate | Zolpidem Tartrate | 356 | 90 |
| Raloxifene Hcl | Raloxifene Hcl | 354 | 74 |
| Bepotastine Besilate | Bepotastine Besilate | 341 | 69 |
| Alendronate Sodium | Alendronate Sodium | 336 | 74 |
| Fenofibrate | Fenofibrate Nanocrystallized | 313 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 78 |
| Azithromycin | Azithromycin | 289 | 208 |
| Meloxicam | Meloxicam | 243 | 98 |
| Jardiance | Empagliflozin | 235 | 42 |
| Finasteride | Finasteride | 234 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 233 | 57 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 227 | 71 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 208 | 56 |
| Clobetasol Propionate | Clobetasol Propionate | 192 | 51 |
| Celecoxib | Celecoxib | 190 | 55 |
| Gabapentin | Gabapentin | 189 | 47 |
| Halobetasol Propionate | Halobetasol Propionate | 185 | 48 |
| Mometasone Furoate | Mometasone Furoate | 178 | 51 |
| Ketoconazole | Ketoconazole | 165 | 50 |
| Mupirocin | Mupirocin | 158 | 72 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 152 | 43 |
| Meclizine Hcl | Meclizine Hcl | 148 | 88 |
| Metformin Hcl Er | Metformin Hcl | 145 | 33 |
| Farxiga | Dapagliflozin Propanediol | 144 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 139 | 38 |
| Naproxen | Naproxen | 139 | 61 |
| Famotidine | Famotidine | 129 | 60 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 126 | 35 |
| Januvia | Sitagliptin Phosphate | 120 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 34 |
| Labetalol Hcl | Labetalol Hcl | 118 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 28 |
| Synthroid | Levothyroxine Sodium | 116 | 29 |
| Betamethasone Valerate | Betamethasone Valerate | 112 | 37 |
| Atenolol | Atenolol | 109 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 22 |
| Rybelsus | Semaglutide | 108 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 25 |
| Donepezil Hcl | Donepezil Hcl | 107 | 23 |
| Eliquis | Apixaban | 107 | 26 |
| Nifedipine Er | Nifedipine | 106 | 20 |
| Memantine Hcl Er | Memantine Hcl | 99 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 95 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 92 | 44 |
| Procto-Med Hc | Hydrocortisone | 92 | 24 |
| Glipizide Er | Glipizide | 90 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 89 | 21 |
| Glipizide | Glipizide | 89 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 87 | 18 |
| Prednisone | Prednisone | 86 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 23 |
| Hydrocortisone | Hydrocortisone | 79 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 20 |
| Nitroglycerin | Nitroglycerin | 79 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 34 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 77 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 77 | 18 |
| Mirtazapine | Mirtazapine | 70 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 70 | 20 |
| Ezetimibe | Ezetimibe | 67 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 66 | 35 |
| Ibuprofen | Ibuprofen | 64 | 33 |
| Lisinopril | Lisinopril | 64 | 19 |
| Restasis | Cyclosporine | 64 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 14 |
| Vemlidy | Tenofovir Alafenamide | 63 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | suppressed |
| Lidocaine | Lidocaine | 61 | 16 |
| Furosemide | Furosemide | 60 | 33 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 58 | 11 |
| Prolia | Denosumab | 57 | 35 |
| Felodipine Er | Felodipine | 56 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 56 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 13 |
| Carvedilol | Carvedilol | 52 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 14 |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 50 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 50 | suppressed |
| Sucralfate | Sucralfate | 50 | 22 |
| Telmisartan | Telmisartan | 50 | suppressed |
| Ciclopirox | Ciclopirox | 48 | 17 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 47 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 34 |
| Ozempic | Semaglutide | 45 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 12 |
| Single Use Swab | Alcohol Antiseptic Pads | 43 | 15 |
| Spironolactone | Spironolactone | 42 | 13 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 36 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 36 | 14 |
| Linzess | Linaclotide | 36 | suppressed |
| Silodosin | Silodosin | 36 | suppressed |
| Colchicine | Colchicine | 35 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Pregabalin | Pregabalin | 33 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Nateglinide | Nateglinide | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | 27 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | 21 |
| Propranolol Hcl | Propranolol Hcl | 28 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Desoximetasone | Desoximetasone | 26 | suppressed |
| Acarbose | Acarbose | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 18 |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 20 |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 21 | 17 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Dupixent Syringe | Dupilumab | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | 15 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | 11 |
| Nexletol | Bempedoic Acid | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Prevident | Fluoride (Sodium) | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Xiidra | Lifitegrast | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Diovan | Valsartan | 13 | suppressed |
| Flunisolide | Flunisolide | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Zileuton Er | Zileuton | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,240.70 · 56 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CIBINQO, CREON, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EUCRISA, FARXIGA, LITFULO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Symbravo, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error